anti-anb3 integrin mAbs (Barbara Ann Karmanos Cancer Institute)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameanti-anb3 integrin mAbs (Barbara Ann Karmanos Cancer Institute)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionIntegrin antagonists
TargetsIntegrin
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBarbara Ann Karmanos Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBarbara Ann Karmanos Cancer Institute
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A